Chronic kidney disease (CKD) is a progressive loss of kidney function that often results in end-stage kidney disease (ESKD) and requires treatment with dialysis. Anemia is a frequent CKD complication characterized by symptoms such as fatigue, weakness, and diminished concentration; more than half of CKD patients experience anemia by stage 4 CKD compared to only 8% at stage 1. Patients frequently report CKD-related anemia burdens of increased morbidity and mortality, excessive health care costs, work productivity impairment, and lower quality of life. This burden weighs disproportionally upon underserved patient populations that include racial and ethnic minorities. Clinicians in the CKD field have the important undertaking of appropriate anemia recognition and treatment for all patients and must thus understand this crucial aspect of CKD management.
In the first activity of this CME Outfitters BriefCase series, expert faculty utilize case-based learning to evaluate the burden of CKD-related anemia, with a focus on patient populations undergoing dialysis who are at risk for receiving poorer care and experiencing worse outcomes.
Evaluate the burden of CKD-related anemia, particularly among underserved patient populations on dialysis who are at risk for receiving poorer care and experiencing worse outcomes
This educational activity is supported by an educational grant from GSK.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in nephrology or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Kelepouris reports the following financial relationships:
Advisory Board: AstraZeneca; Bayer: Boehringer Ingelheim Pharmaceuticals Inc. and Lilly Alliance; CSL Vifor; and GSK
Consultant: Travere Therapeutics, Inc.
Disclosures were obtained from the following peer reviewers and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).